* Cambridge Antibody Technology, of Cambridge,England, received a $2 million equity investment fromGenentech Inc., of South San Francisco, for a non-exclusive license to the U.K.-based company's antibodylibraries and associated technologies. In addition,Cambridge Antibody could receive milestone paymentsand royalties on products derived from the collaboration.
* Lidak Pharmaceuticals Inc., of La Jolla, Calif., receivedFDA clearance to begin Phase I/II studies of its largemultivalent immunogens (LMIs) for malignantmelanoma. LMIs are combinations of isolated tumorantigens and cell-size microspheres, which are injected incancer patients and are designed to stimulate tumor-specific cytotoxic T lymphocytes.
* Ligand Pharmaceuticals Inc., of San Diego, andAllergan Ligand Retinoid Therapeutics Inc. (ALRT)settled their patent battle with La Jolla Cancer ResearchFoundation, of La Jolla, Calif., and SRI International, ofMenlo Park, Calif. The settlement declares the validity offour U.S. patents on retinoid technology licensed toLigand and ALRT by the Salk Institute for BiolgicalStudies in La Jolla. The litigating parties also agreed to across-licensing of patents. No damage payments weremade. ALRT is a joint venture between Ligand andAllergan Inc., of Irvine, Calif.
(c) 1997 American Health Consultants. All rights reserved.